PTAB Struggles To Parse Arguments In Acne Drug Patent Suit

Law360 (June 5, 2019, 10:08 PM EDT) -- The Patent Trial and Appeal Board seemed to struggle Wednesday to grasp the argument posed by drugmaker Almirall as it attempted to fend off a bid to invalidate its patent covering the acne drug Aczone, with one judge saying the attorney's responses "raised more questions than answers."

The judges hammered the parties on their key dispute over the makeup of a gelling compound used in the patent and whether it would have been obvious for a person with ordinary skill in the field to create it using information already available to them.

Generic drugmaker Amneal Pharmaceuticals argues that the patent's claims...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Related

Sections

PTAB Case Information

Case Title

Subscribers Only


Case Number

Subscribers Only

Date Filed

February 12, 2018


Case Title

Subscribers Only


Case Number

Subscribers Only

Date Filed

November 6, 2018

Law Firms

Companies

Government Agencies

Patents